The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for ...

The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...

GSK’s MenABCWY vaccine is an injectable suspension intended for intramuscular use. It comes with a vial of lyophilised ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active ...

Meningococcal infections can lead to severe, sometimes deadly, bloodstream infections, and severe swelling in the brain and ...

▎药明康德内容团队编辑GSK日前宣布，美国FDA已批准其组合疫苗Penmenvy（MenABCWY）上市，在10~25岁人群中使用。这款疫苗针对脑膜炎球菌中最常见的5大血清群，它们通常是导致侵袭性脑膜炎球菌病（IMD）的原因。此前，该疗法入选了业内知 ...

GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

GSK’s five-in-one meningococcal vaccine Penmenvy has been approved by the US Food and Drug Administration (FDA) for use in individuals aged from ten to 25 years. Invasive meningococcal disease (IMD) ...